Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Heart Failure × Ado-Trastuzumab Emtansine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 7 Salivary Gland Neoplasms 2 Neoplasms 2 Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants 1 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Solid Tumors 1 Pathologic Complete Response 1 Hemangiosarcoma 1 Heart Failure 1 HER2-positive Metastatic Breast Cancer 1 HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1 Advanced Breast Cancer 1 Adenocarcinoma Of Esophagus 1

Interventions

sacubitril and valsartan sodium hydrate drug combination 2 Rituximab 2 pertuzumab 1 pegfilgrastim 1 obinutuzumab 1 nicotinamide-beta-riboside 1 dapagliflozin 1 acalabrutinib 1 Vincristine 1 Valsartan 1 Trastuzumab 1 Standard of Care 1 Specimen Handling 1 Pyruvic Acid 1 Prednisolone 1 Practice Guidelines as Topic 1 Ogivri 1 Mesenchymal Stem Cell Transplantation 1 Lenalidomide 1 Eplerenone 1 Electronic Health Records 1 Echocardiography 1 Doxorubicin 1 Dexrazoxane 1 Cyclophosphamide 1 Cardiac Resynchronization Therapy 1 Angiotensin-Converting Enzyme Inhibitors 1 Adrenergic beta-Antagonists 1 Ado-Trastuzumab Emtansine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04680442 2025-04-06

SCHOLAR-2

Population Health Research Institute

Phase 2 Recruiting

Breast Neoplasms, Heart Failure

Data powered by HemOnc (CC BY 4.0) Colophon ⚡